A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Allergan
Age
18–50
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Pre-menopausal women, 18-50 years, inclusive.
Cyclic abnormal uterine bleeding (heavy or prolonged).
Menstrual blood loss (MBL) of ≥ 80 mL as measured by the alkaline hematin method in the first 8 days of menses.
Minimum of one discrete leiomyoma observable by transvaginal ultrasound.
Endometrial biopsy without evidence of malignancy or atypical or non-atypical hyperplasia
You may not be if
History of uterine surgery that would interfere with the study endpoints.
Known coagulation disorder including bleeding disorder or clotting disorder.
History of, or current uterine, cervix, ovarian, or breast cancer.
Alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), or total bilirubin two times or greater than the upper limit of normal rang
Clareo Health | A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas
